Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
1.239
+0.029 (+2.38%)
Streaming Delayed Price
Updated: 12:09 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC)
October 16, 2023
Via
ACCESSWIRE
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
October 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
October 13, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
October 11, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted European Patent for its Core Technology
October 03, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
September 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces 1-for-26 Reverse Share Split
September 20, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
September 12, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)
August 15, 2023
Via
ACCESSWIRE
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
August 14, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
August 10, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
August 09, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
August 01, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
August 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
July 14, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 30, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 21, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada
June 07, 2023
From
Jeffs' Brands Ltd
Via
GlobeNewswire
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
June 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
June 02, 2023
Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitation
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
May 30, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program
May 08, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 02, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
April 21, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.